Capmatinib
FDA grants Tabrecta regular approval for certain patients with non-small cell lung cancer
The FDA approved capmatinib for treatment of certain adults with metastatic non-small cell lung cancer.
FDA expands indication of FoundationOne Liquid CDx for use with Tabrecta
The FDA approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify MET exon 14 skipping in patients with metastatic non-small cell lung cancer, according to a company-issued press release.
Precision medicine for lung cancer a ‘rapidly evolving field’
Molecular oncology is a rapidly evolving field with exciting results.
VIDEO: Framing ASCO findings from a patient advocate perspective
In this video, Upal Basu Roy, PhD, MPH, vice president of research at LUNGevity Foundation, spoke with Healio about three important presentations in non-small cell cancer from this year’s ASCO annual meeting.
FDA approves Tabrecta for certain patients with metastatic NSCLC
Capmatinib shows efficacy in lung cancer subset, including patients with brain metastases
The investigational MET inhibitor capmatinib appeared effective for treatment of certain patients with metastatic non-small cell lung cancer, including those with brain metastases, according to cohort analyses of the phase 2 GEOMETRY mono-1 study presented at the virtual American Association for Cancer Research Annual Meeting.
FDA grants capmatinib priority review for non-small cell lung cancer subset
The FDA granted priority review to capmatinib for the treatment of patients with advanced non-small cell lung cancer who harbor MET exon 14 skipping mutations.